Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated July 23, 2021.

Hold Biocon: target of Rs 400: ICICI Direct

ICICI Direct recommended hold rating on Biocon with a target price of Rs 400 in its research report dated April 29, 2021.

Neutral Biocon; target of Rs 385: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 385 in its research report dated January 22, 2021.

Buy Biocon; target of Rs 470: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated January 22, 2021.

Hold Biocon; target of Rs 450: ICICI Direct

ICICI Direct recommended hold rating on Biocon with a target price of Rs 450 in its research report dated January 22, 2021.

Syngene: A preferred partner of global pharma innovators; accumulate

Beyond contract research, another trend to watch for Syngene is the pickup in contract manufacturing business in biologics and APIs

Buy Biocon: target of Rs 520: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research report dated December 28, 2020.

Laurus Labs: Foray into biotech adds new lever of growth; accumulate

Efforts to diversify will open up new opportunities for Laurus Labs and make it move towards a higher-margin trajectory

Neutral Biocon; target of Rs 400: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 400 in its research report dated October 23, 2020.

Buy Biocon; target of Rs 495: Sharekhan

Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 495 in its research report dated October 23, 2020.

Buy Biocon; target of Rs 500: ICICI Direct

ICICI Direct is bullish on Biocon recommended buy rating on the stock with a target price of Rs 500 in its research report dated October 23, 2020.

Cadila: a formidable play in Covid times and beyond

Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

Neutral Biocon; target of Rs 450: Motilal Oswal

Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 450 in its research report dated July 25, 2020.

Buy Biocon; target of Rs 490: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 490 in its research report dated July 24, 2020.

Buy Biocon; target of Rs 390: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 390 in its research report dated May 18, 2020.

Buy Biocon; target of Rs 330: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 330 in its research report dated July 26, 2019.

Buy Biocon; target of Rs 730: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 730 in its research report dated April 26, 201

Buy Biocon; target of Rs 760: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 760 in its research report dated January 25, 2019.

Buy Biocon; target of Rs 410: Axis Direct

Axis Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 410 in its research report dated November 02, 2017.

Buy Biocon; target of Rs 380: Axis Direct

Axis Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 380 in its research report dated 23 August 2017.

Buy Biocon; target of Rs 450: Axis Direct

Axis Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 450 in its research report dated August 02, 2017.

Sell Biocon; target of Rs 330: Motilal Oswal

Motilal Oswal is bullish on Biocon has recommended Sell rating on the stock with a target price of Rs 330 in its research report dated July 28, 2017

Hold Biocon; target of Rs 375: ICICI Direct

ICICI Direct has recommended hold rating on Biocon with a target price of Rs 375 in its research report dated July 14, 2017.

Hold Biocon; target of Rs 1000: Axis Direct

Axis Direct recommended hold rating on Biocon with a target price of Rs 1000 in its research report dated May 04, 2017.

Hold Biocon; target of Rs 1020: ICICI Direct

ICICI Direct recommended hold rating on Biocon with a target price of Rs 1020 in its research report dated May 02, 2017.